Companion Animals

Companion Dog Arthritis Solensia Biologic Treatment

Anti-NGF biologic treatments represent a new generation of canine arthritis pain management that improves quality of life significantly.

Key Facts

Librela (bedinvetmab) is a monthly injectable anti-NGF antibody for dog arthritis pain
Clinical trials show significant improvement in pain and mobility scores after two months
Unlike NSAIDs, anti-NGF biologics do not carry kidney or liver toxicity risks
The drug specifically targets nerve growth factor, a key pain signalling molecule
Senior dogs with arthritis who cannot tolerate NSAIDs can now be treated effectively

Welfare Considerations

Canine arthritis causes chronic pain affecting mobility, play, and quality of life. The development of anti-NGF biologics provides an effective treatment option for dogs who cannot tolerate traditional NSAIDs due to kidney or liver disease - conditions common in elderly dogs. This therapeutic advance means fewer arthritic dogs need to suffer without adequate pain management.

What You Can Do

Discuss anti-NGF biologic treatment options with your vet if your dog has arthritis
Assess your arthritic dog's response to treatment using validated pain scoring tools
Advocate for pain management access to be a welfare standard in senior dog care guidelines